Founder
DB
Duality Biologics
InactiveDuality Biologics is a clinical‑stage company that develops next‑generation antibody‑drug conjugate (ADC) therapeutics for oncology and autoimmune diseases. Leveraging proprietary linker chemistries, optimized payloads, and site‑specific conjugation, its platforms deliver higher potency, reduced off‑target toxicity, and scalable GMP‑compatible manufacturing. The company offers modular ADC constructs for licensing or co‑development to pharma and biotech partners.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$90MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current antibody‑drug conjugate (ADC) therapies often suffer from limited efficacy, off‑target toxicity, and manufacturing challenges, leaving many cancer and autoimmune patients without effective targeted treatments.
Solution
Duality Biologics addresses these gaps by developing next‑generation ADC platforms that incorporate advanced linker chemistries, optimized payloads, and site‑specific conjugation technologies to enhance therapeutic index. The company leverages extensive proprietary intellectual property to create modular ADC constructs that can be rapidly adapted to a variety of disease targets. By advancing candidates into clinical stages for both oncology and autoimmune indications, Duality aims to deliver more potent and safer targeted therapies. Their platform enables scalable manufacturing and facilitates partnership opportunities for co‑development and licensing.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to develop or license advanced ADC therapeutics for oncology and autoimmune disease programs.
Features
- Multiple proprietary ADC technology platforms covering novel linkers, payloads, and site‑specific conjugation methods
- Engineered antibodies with improved stability and reduced off‑target effects
- Scalable, GMP‑compatible manufacturing processes for clinical‑grade ADCs
- Broad pipeline spanning oncology and autoimmune disease indications at clinical stage
- Global patent portfolio protecting key platform components and therapeutic candidates